Literature DB >> 9924923

The clinico-ophthalmological spectrum of antiphospholipid syndrome.

D Giorgi1, C B Gabrieli, L Bonomo.   

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable disorder with highly variable symptomatology including ocular manifestations. Antiphospholipid antibodies (aPL) are the serologic markers of this clinical entity. Our aim was to note the main associated ocular features of APS and elucidate which pathogenic mechanisms may participate. Retinal vascular thrombosis and different neuro-ophthalmologic manifestations, such as optic neuropathy and amaurosis fugax, may be considered as the ocular hallmarks of this syndrome. Ocular features due to aPL-induced thrombosis should be treated with anticoagulant drugs. Conversely, for the treatment of ocular features due to immunological mechanisms such as vasculitis, immunosuppressive regimes seem to be more appropriate.

Entities:  

Mesh:

Year:  1998        PMID: 9924923     DOI: 10.1076/ocii.6.4.269.4025

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  4 in total

Review 1.  Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome.

Authors:  Rafid Mustafa
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-30       Impact factor: 6.030

Review 2.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

3.  Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series.

Authors:  Evangelia Tsironi; Nikolaos Gatselis; Maria G Kotoula; Kalliopi Zachou; Maria Pefkianaki; Fani Zacharaki; Dimitrios Z Chatzoulis; George N Dalekos
Journal:  Cases J       Date:  2009-10-20

4.  Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia.

Authors:  Hee Kyung Yang; Ki Won Moon; Min Jung Ji; Sang Beom Han; Jeong-Min Hwang
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.